

Tuberculosis profile: Madagascar

Population 2019: 27 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	63 000 (41 000-90 000)	233 (151-333)
HIV-positive TB incidence	780 (500-1 100)	2.9 (1.9-4.2)
MDR/RR-TB incidence**	430 (81-1 100)	1.6 (0.3-4)
HIV-negative TB mortality	12 000 (7 100-18 000)	44 (26-67)
HIV-positive TB mortality	280 (180-410)	1.1 (0.67-1.5)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	0.49% (0.09-1.2)
Previously treated cases	5.9% (0.59-17)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	59% (41-92)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	20% (10-33)

TB case notifications, 2019

Total new and relapse	37 220
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	67%
- % pulmonary	80%
- % bacteriologically confirmed ^	85%
- % children aged 0-14 years	8%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	35%
- % men	57%
Total cases notified	37 679

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	309	1.2%
- on antiretroviral therapy	226	73%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	0.033%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	4.4%
Laboratory-confirmed cases - MDR/RR-TB ^^	78
Patients started on treatment - MDR/RR-TB ^^	50
Laboratory-confirmed cases - XDR-TB ^^	0
Patients started on treatment - XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	32

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	83%	34 317
Previously treated cases, excluding relapse, registered in 2018	66%	419
HIV-positive TB cases registered in 2018	80%	339
MDR/RR-TB cases started on second-line treatment in 2017	67%	18
XDR-TB cases started on second-line treatment in 2017		0

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	36% (33-39)
---	----------------

TB financing

National TB budget, 2020 (US\$ millions)	3
- Funding source, domestic	0%
- Funding source, international	100%
- unfunded	0%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)